{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T16:50:01Z","timestamp":1770483001178,"version":"3.49.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1111\/igc.0b013e3181bda1a7","type":"journal-article","created":{"date-parts":[[2010,12,3]],"date-time":"2010-12-03T14:12:38Z","timestamp":1291385558000},"page":"1505-1510","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Carboplatin and Paclitaxel in Combination With Oral Enzastaurin in Advanced Ovarian or Primary Peritoneal Cancer Results From a Safety Lead-in Study"],"prefix":"10.1016","volume":"19","author":[{"given":"Ignace","family":"Vergote","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederic","family":"Amant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gulten","family":"Oskay-\u00d6ezcelik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luna","family":"Musib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Laure","family":"Michel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christelle","family":"Darstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marek","family":"Kania","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Bauknecht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jalid","family":"Sehouli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1111\/IGC.0b013e3181bda1a7_bb0005","doi-asserted-by":"crossref","first-page":"viii7","DOI":"10.1093\/annonc\/mdi961","article-title":"2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004)","volume":"16","author":"du Bois","year":"2005","journal-title":"Ann Oncol."},{"key":"10.1111\/IGC.0b013e3181bda1a7_bb0010","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/1098-2388(200007\/08)19:1<3::AID-SSU2>3.0.CO;2-S","article-title":"Ovarian cancer: epidemiology, biology, and prognostic factors","volume":"19","author":"Holschneider","year":"2000","journal-title":"Semin Surg Oncol."},{"key":"10.1111\/IGC.0b013e3181bda1a7_bb0015","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1200\/JCO.2007.11.1088","article-title":"Novel approaches in advancing the treatment of epithelial ovarian cancer: the role of angiogenesis inhibition","volume":"25","author":"Martin","year":"2007","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181bda1a7_bb0020","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ctrv.2007.07.019","article-title":"Molecular-targeted therapies: lessons from years of clinical development","volume":"34","author":"Rosa","year":"2008","journal-title":"Cancer Treat Rev."},{"key":"10.1111\/IGC.0b013e3181bda1a7_bb0025","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.advenzreg.2005.02.017","article-title":"The evolution of cancer research and drug discovery at Lilly Research Laboratories","volume":"45","author":"Pearce","year":"2005","journal-title":"Advan Enzyme Regul."},{"key":"10.1111\/IGC.0b013e3181bda1a7_bb0030","doi-asserted-by":"crossref","first-page":"7462","DOI":"10.1158\/0008-5472.CAN-05-0071","article-title":"The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts","volume":"65","author":"Graff","year":"2005","journal-title":"Cancer Res."},{"key":"10.1111\/IGC.0b013e3181bda1a7_bb0035","doi-asserted-by":"crossref","first-page":"4092","DOI":"10.1200\/JCO.2005.05.3447","article-title":"Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer","volume":"24","author":"Carducci","year":"2006","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181bda1a7_bb0040","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1200\/JCO.2006.09.3146","article-title":"Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma","volume":"25","author":"Robertson","year":"2007","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181bda1a7_bb0045","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1200\/jco.2005.23.16_suppl.1504","article-title":"Results from phase II trial of enzastaurin (LY317615) in patients with recurrent high grade gliomas","volume":"23","author":"Fine","year":"2005","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181bda1a7_bb0050","doi-asserted-by":"crossref","first-page":"8097","DOI":"10.1158\/1078-0432.CCR-05-1152","article-title":"Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel","volume":"11","author":"Henningsson","year":"2005","journal-title":"Clin Cancer Res."},{"key":"10.1111\/IGC.0b013e3181bda1a7_bb0055","first-page":"4026","article-title":"Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme","volume":"54","author":"Harris","year":"1994","journal-title":"Cancer Res."},{"key":"10.1111\/IGC.0b013e3181bda1a7_bb0060","first-page":"5543","article-title":"Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8","volume":"54","author":"Rahman","year":"1994","journal-title":"Cancer Res."},{"key":"10.1111\/IGC.0b013e3181bda1a7_bb0065","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/S0022-3565(25)12102-2","article-title":"Variability in human cytochrome P450 paclitaxel metabolism","volume":"275","author":"Sonnichsen","year":"1995","journal-title":"J Pharmacol Exp Ther."},{"key":"10.1111\/IGC.0b013e3181bda1a7_bb0070","doi-asserted-by":"crossref","first-page":"517","DOI":"10.5414\/CPP39517","article-title":"Screening for inhibitory effects of antineoplastic agents on CYP3A4 in human liver microsomes","volume":"39","author":"Baumhakel","year":"2001","journal-title":"Int J Clin Pharmacol Ther."},{"key":"10.1111\/IGC.0b013e3181bda1a7_bb0075","doi-asserted-by":"crossref","first-page":"6502","DOI":"10.1158\/1078-0432.CCR-05-1076","article-title":"Flat dosing of carboplatin is justified in adult patients with normal renal function","volume":"12","author":"Ekhart","year":"2006","journal-title":"Clin Cancer Res."},{"key":"10.1111\/IGC.0b013e3181bda1a7_bb0080","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0020-7292(99)00070-3","article-title":"FIGO staging of gynecologic cancer. 1994-1997 FIGO Committee on Gynecologic Oncology. International Federation of Gynecology and Obstetrics","volume":"65","author":"Pecorelli","year":"1999","journal-title":"IntJ Gynaecol Obstet."},{"key":"10.1111\/IGC.0b013e3181bda1a7_bb0085","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron."},{"key":"10.1111\/IGC.0b013e3181bda1a7_bb0090","doi-asserted-by":"crossref","first-page":"14076","DOI":"10.1200\/jco.2007.25.18_suppl.14076","article-title":"Effects of a proton pump inhibitor (lansoprazole) and food on the bioavailability of enzastaurin administered as single oral doses to healthy subjects","volume":"25","author":"Welch","year":"2007","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181bda1a7_bb0095","unstructured":"National Cancer Institute. Cancer Therapy Evaluation Program: Common Terminology Criteria for Adverse Events v3.0 (CTCAE). National Cancer Institute."},{"key":"10.1111\/IGC.0b013e3181bda1a7_bb0100","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1002\/sim.1783","article-title":"Sample sizes for clinical trials with normal data","volume":"23","author":"Julious","year":"2004","journal-title":"Stat Med."},{"key":"10.1111\/IGC.0b013e3181bda1a7_bb0105","doi-asserted-by":"crossref","first-page":"6410","DOI":"10.1158\/1078-0432.CCR-07-0064","article-title":"Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European Organization for Research and Treatment of CancerVPharmacology and Molecular Mechanisms Group and New Drug Development Group","volume":"13","author":"Joerger","year":"2007","journal-title":"Clin Cancer Res."}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2FIGC.0b013e3181bda1a7","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24027634?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24027634?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1111\/IGC.0b013e3181bda1a7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T22:17:06Z","timestamp":1753222626000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24027634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["S1048891X24027634"],"URL":"https:\/\/doi.org\/10.1111\/igc.0b013e3181bda1a7","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2009,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Carboplatin and Paclitaxel in Combination With Oral Enzastaurin in Advanced Ovarian or Primary Peritoneal Cancer Results From a Safety Lead-in Study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/IGC.0b013e3181bda1a7","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 IGCS and ESGO","name":"copyright","label":"Copyright"}]}}